文章摘要
李彩云 张奕霞 陈宁宁 李燕利 张晖.内皮抑素对眼部新生血管抑制的研究进展[J].,2014,14(4):798-800
内皮抑素对眼部新生血管抑制的研究进展
Recent Advances of Endostatin in the Inhibition of OcularNeovascularization for the Triple Negative Breast Cancer
  
DOI:
中文关键词: 内皮抑素  眼部新生血管  治疗
英文关键词: Endostatin  Ocular neovascularization  Treatment
基金项目:
作者单位
李彩云 张奕霞 陈宁宁 李燕利 张晖 石河子大学医学院
石河子大学医学院第一附属医院眼科 
摘要点击次数: 629
全文下载次数: 3098
中文摘要:
      眼部新生血管存在于多种常见的眼病的发展过程中,对视功能危害大,是致盲的主要原因之一。包括糖尿病视网膜病变,视 网膜栓塞,早产儿视网膜病变,老年性黄斑变性等眼病。由于其发病机制尚未完全清楚,因此目前仍无确切有效的药物治疗方法。 内皮抑素( Endostatin,ES) 是1997 年首先从小鼠血管内皮瘤EOMA细胞培养上清中发现的, 是胶原XⅧ的蛋白降解产物,分子质 量约为20KD,为胶原XⅧC端非胶原区(NC1) 内的184 个氨基酸片段。ES 是目前发现的最强的血管生成抑制因子,可抑制 VEGF,bFGF,EGF等刺激的血管内皮细胞的增殖和迁移, 诱导其凋亡,进而抑制新生血管的形成。通过抑制眼部新生血管的实 验研究表明,ES是当前抗新生血管疗法中最有潜力的一种新药。本文就内皮抑素的结构特点及其对眼部新生血管的治疗研究进 展作一综述。
英文摘要:
      Ocular neovascularization is a phenomenon observed in various kinds of eye diseases, which is harm to visual function and it is one of the main causes of blindness. The diseases include diabetic retinopathy, retinal embolism, retinopathy of prematurity age-related macular degeneration , etc. There is still no effective drug treatment as its mechanism is not completely clear. Endostatin (Endostatin, ES)a 20 kDa with 184 amino fragment of the NCI domain of collagen XVIII, was first discovered from hemangioendothelioma EOMA in cell culcure supernatant of mouse in 1997. ES inhibits the formation of new blood vessels by induction of apoptosis and inhibiting VEGF, bFGF, EGF which stimulated the proliferation and migration of vascular endothelial cells, and it is the strongest angiogenesis inhibitor. Experiments have shown that ES is the most potential new drug in the anti-neovasculatural therapy. This article reviewed the advances in the treatment of ocular neovascularization and structure of ES.
查看全文   查看/发表评论  下载PDF阅读器
关闭